Key Insights

Highlights

Treatment Research

3 treatments under study, led by Veltuzumab And 90yepratuzumab Tetraxetan

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 1/2 (1)

Trial Status

Withdrawn1

Clinical Trials (1)

Showing 1 of 1 trials
NCT01101581Phase 1/2Withdrawn

Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL

Showing all 1 trials

Research Network

Common Treatments

  • Veltuzumab And 90yepratuzumab Tetraxetan1
  • Veltuzumab1
  • 90yepratuzumab Tetraxetan1

Active Sponsors

  • Gilead Sciences1

Top Investigators

Related Conditions

  • Non Hodgkins Lymphoma1
  • Diffuse Large Bcell Lymphoma1
  • Nhl1

Activity Timeline